Women (175) 
INTRODUCTION
In early March 1988 the University Hospital Dljkzlgt was confronted with a hepatitis B epldemm in women who had undergone m wtro fertilization I 2 All women (n= 175) who had undergone m vttro fertlhzatlon (IVF) since November 1987 but were without signs of hepatitis B virus (HBV) infection at first screening, as well as their sexual partners, were offered passwe active immunization 3 The rationale for starting passive active lmmumzation 6 18 weeks after HBV-exposure was to modify Infection in females and to prevent infection in males All women followed an 'intensive' immunization scheme consisting of hepatitis B lmmunoglobuhn (HBIg) on day 1 and 1 month later and recombinant vaccine on day 1 and 1, 2 and 6 months later Male partners who may have been exposed to HBV for several weeks also received HBIg on day 1 and 1 month later and recombinant vaccine on day 1 and 1 and 6 months later
In this study the levels of HBV protective antibodies (antl-HBs ~> 10mlU ml -x) induced by passive active immunization were examined An explanation was 
MATERIALS AND METHODS

Patients and controls
From 2 November 1987 until 2l January 1988 175 women undergoing 1VF might have been exposed to hepatitis B virus Tissue culture medium supplemented with 7 5% heat-inactivated (30 mln 56°C) human serum, which was used for pre-embryo cultures or other procedures during in wtro fertlllzatmn, seemed to be the most probable source of infection The human serum was regularly pooled from blood samples of 15-20 pregnant women All donors were individually screened for hepatitis B virus Due to a breakdown m communication between the outpatient chnlc of the Department of Obstetrics and the IVF laboratory, the results of the routine screening of sera from pregnant women for HBsAg temporarily did not reach the IVF laboratory and an HBV-posJtlve serum was apparently included in the pooled serum On 2 March 1988 the epidemic was discovered by reports on three cases of jaundice All women at risk and their partners were Immediately requested to visit the University Hospital Dljkzlgt for medical examination Blood samples were obtained from 174 potentially exposed women and 167 sexual partners and preventive measures were advised These measures Included hygiene, use of condoms during sexual mtercourse and passtve active lmmumzatlon Analysis of the mcldence of HBV mfectlon in 7 day cohorts of m wtro fertlhzatlon treatment finally revealed that the period of mfectlous exposure only extended from 2 November to 13 December 1987 (period ! ), thts period comctded with the use of one of the two batches of pooled serum used m tissue culture None of the women treated from 14 December 1987 to 21 January 1988 (period 2) developed signs of a hepatitis B infection
Of the total of 175 women, 128 were exposed to the lnfecttous batch of pooled serum, the remamlng 47 women were not exposed to infectious culture medtum Of the 128 women exposed m period 1, 30 had chnlcal stgns of HBV or were HBsAg-poslttve and pregnant at first presentaUon One woman did not dehver serum and another woman was protected by previous vaccmauon Therefore lmmuntzatlon was started m 96 women Due to the presence of markers of hepatitis B m the pre-IVF serum (9 cases) or in serum taken at first presentatton (49 cases), tmmuntzatlon was stopped in 58 of the 96 women (Table 1) The remamlng 38 women contmued tmmuntzatlon and may be charactertzed as exposed but not infected (group 1) A second group of vaccmees (group 2) ts composed of women who recetved IVF treatment m period 2, the mformat~on that the culture medium used m period 2 was not Infectious became available about 2 months after immunization had started lmmunlzatton was completed m the large majority of women The other lmmuntzatton groups comprised the partners The spouses of 79 HBV infected women by IVF treatment were labelled as group 3 The spouses of 49 non-infected women from period I together with the spouses of 47 women treated in pertod 2 comprtsed group 4 Further details of the four lmmunlzatton groups are given m Tables I and 2 The control groups, hospital personnel tmmuntzed m the same pertod, conststed of 84 females (group 5) and 53 males (group 6) all women except those wtth chnlcal hepatttlS or pregnant women with HBsAg-posltlvtty, as determined by rapid blood testing with the reversed passive haemagglutmatton assay (Hepatest, Wellcome Laboratories, Beckenham, UK) at first presentation A second dose of HBIg was gtven 1 month later Additional doses of vaccme were admmtstered 1, 2 and 6 months later HBIg and vaccine were dtscontlnued as soon as HBV markers not due to HBIg or vaccine were detected in the serum Male partners recetved HBlg on day 1 and 1 month later and HBvaxDNA (10#g) on day 1 and 1 and 6 months later Immuntzatlon was dtscontlnued when vacclnees were found to be poslttve for HBsAg, antt-HBc or antt-HBs at screening After 4 months, partners of HBV-poslttve women (group 3) received an addttlonal dose of HBIg if the antl-HBs tttre was below 20 mIU mland hkely to fall below 10 mIU ml-1 before the booster vaccine injection at 6 months Hospital personnel, who served as controls, recetved HBvaxDNA (10/~g) from the same lot according to the regular schedule on day 1 and 1 and 6 months later without HBIg (Table 2 ) HBIg was admmtstered by lnjectton] m rata the buttock, HB-vacclne was injected 1 m into the deltoid muscle
Blood sampling and laboratory methods
Pre-lmmuntzatton serum samples were obtained m March 1988 For females follow-up blood samples were drawn 1,2, 6 and 7 months after the first vaccme ln lectlon For males, blood samples were taken after 1, 4, 6 and 7 months All pre-lmmuntzatton samples from groups 1 4 as well as follow-up samples were tested for HBsAg, antl-HBc and antl-HBs Blood samples from controls were tested for antl-HBc and antI-HBs after 7 months Blood samples were tested for HBsAg and antl-HBc by enzyme tmmunoassay (Abbott Laboratortes, Chtcago, IL, USA) Antl-HBs was tested by radio lmmunoassay (Ausab, Abbott Laboratories) and quantified using the WHO standard preparahon 4 A protective antt-HBs level was defined as ant]-HBs concentration ~> 10 mlU ml -~, in the absence of other HBV markers
Statistical calculations
Stattstlcal differences in protective antl-HBs levels were aMales with ant~-HBs levels below 20 mlU m1-1 at month 4 received an additional HBIg injection bSexual partner exposed but not infected (n = 20) and sexual partner not exposed (n = 32)
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RESULTS
Of the 230 individuals who continued immunization after initial screening (79 females, 151 males), a total of 180 vacclnees (59 females, 121 males) completed the immunization programme Postlmmunlzatlon blood samples were obtained in 148 cases (53 females, 95 males) at month 7 Three women (2 in group l and l in group 2) were excluded from evaluation because they showed more than l0 mIU ml-~ antl-HBs on day l, although antl-HBc tests were negaUve Of the 38 females exposed to HBV (group 1 ), three did not show up for further treatment after month 1 At that Ume, they were all negaUve for both HBsAg and anU-HBc Two females dtd not return for follow-up at month 6 but were HBsAg-negatlve and anU-HBs-posiUve at month 4, another nine women who were HBsAgnegative at month 6 w~th antl-HBs >~ 10 mIU ml-~ did not appear for follow-up at month 7 Of the 37 women who delivered healthy hvlng children 5, nine received one dose of HBIg and HBvaxDNA during pregnancy and 14 received full immunization during pregnancy No adverse reactions to HBIg or vaccine were reported during the observation period of 7 months for vaccmees w~th or w~thout HBV markers at the ttme of first presentation, except for one pregnant vacclnee who had a spontaneous abortion two days after initial immunization
The rate of development of protecUve anubody levels (~> 10 mIU m1-1) is shown m Table 3 One month after the first dose of HBIg and vaccine, protective anubodles were found in 99% (203/205) of the vaccmees Anti-HBs levels were inadequate m two cases (one female m group 2 with 8 mIU ml-1 and one male m group 3 with no detectable antl-HBs) At month 2 protective antibody levels were demonstrated in all females tested At month 4 23% of the men of group 3 and 20% of those of group 4 were unprotected (antl-HBs < l0 mlU ml-1) At month 6 protective antl-HBs levels were measured significantly less often m group 4 males (48%, 95%CI 36 60%) compared with both groups l and 2 (87%, 95%CI 75-99%) and group 3 (81%, 95%CI 71 91%) due to the fact that the antl-HBs level of the majority of the 
vacclnees in group 4 remained just below the arbitrarily chosen level of 10 mIU ml-1 (see GMTs at month 6 in Table 4 ) For group 3 the higher rate of 81% was probably due to the extra dose of HBIg given at month 4 to 25 spouses with antt-HBs tltres < 20 mIU ml-1 Protective antl-HBs levels after completion of vaccmatlon at month 7 were found in all women of groups 1 and 2 (100%) whereas the percentage of males m groups 3 and 4 together 07=95) with protective antibodies at month 7 was 89% (95%C1 83 95%) Table 4 shows the geometric mean tltres of antl-HBs for the various groups Antibody levels of ~ 35 mIU ml-1 at month 1 probably reflect the first dose of HBIg in groups 1-4 Tltres rose to about 45 mIU ml-a at month 2 for women receiving two doses of HBIg and vaccine At month 4, after two doses of HBIg and vaccine, the GMTs for groups 3 and 4 were 16 and 19 mIU ml -~ antl-HBs, respectively A significant increase in antl-HBs was not observed until after the booster dose was given At month 7 the geometric mean tltres of antl-HBs wcre significantly lower for all IVF groups compared with their control groups (group 1 and 2 versus 5 p<0 05, group3and4versus6 p<0001) Since selection of vacclnees due to loss to follow-up may have occurred, the GMT levels of all vacclnees per group were compared with the GMTs of those vacclnees who completed the full immunization scheme in each IVF group No differences in GMTs could be shown at any moment At month 7 an effect of sex on the immune response to hepatitis B vaccine was Indicated by a difference between the female and male groups (IVF groups l + 2 versus 3 +4) The influence of sex was not exhlbtted by control groups 5 and 6 During the observation period of maximal 7 months antl-HBc seroconverslon did not occur in IVF groups All controls were also antl-HBcnegative after Immunization DISCUSSION Hepatitis B lmmunoglobuhn given after exposure to HBV results in prolongation of the incubation period of the virus and partial protection 6-s Beneficial effects of postexposure prophylaxis with hepatitis B plasma vaccine have also been demonstrated in adults 9-a The combination of HBIg and hepatitis B vaccine for postexposure prophylaxis has been shown to increase protection, meaning fewer chnlcal and HBsAg-posltlve Infections, compared with HBIg or HB-vacclne alone ~2-~4 Still, although the spouses of acute hepatitis B patients received HBIg (5 ml) on day 1 and plasma vaccine on day 1 and 1 and 6 months later (20/tg, Merck Sharp & Dohme), 11% exhibited signs of subcllmcal infection (antl-HBc-seroconversmn) at the 3 month examination ~2 Repeated rejections of HBIg can, however, in the case of accidental exposure to HBV malntam protective levels of antl-HBs throughout the Incubation period 7 a5 To accelerate the active immune response, a vacclnatmn schedule with short injection intervals has been proposed for postexposure prophylaxis a6
At the discovery of the HBV epidemic the large majority of patients who had undergone m vitro fertilization were offered postexposure prophylaxis In order to modify the course of the disease an 'intensive' schedule of two doses of HBIg and four doses of vaccine was offered to the females To prevent infection in males the standard ~mmunlzatlon schedule was used with an addmonal dose of HBIg at month 1 a2 No HBV infections, m particular no antl-HBc-seroconverslon, were encountered after the start of passive active Immunization, however, the protective effect of passive active immunization in this setting cannot be proven In view of the absence of a control group with comparable exposure The absence of infections in partners after the start of immunization is remarkable smce they may have been exposed to HBV for several addmonal days or weeks because 34 women were still HBeAg-posltlVe at the start of immumzatlon Sexual contact is said to be an important mode of transmission ~ is However sexual exposure appears to be a less efficient mode of transmlssmn compared w~th the percutaneous route and the chance that men wdl contract hepatitis B wrus during a heterosexual relationship has been estimated to be < 5(¼) t 2
The overall comphance of couples possibly exposed to HBV appeared to be poor The loss to follow-up may have been due to lack of motwatlon since exposure to HBV in IVF treatment period 2 had not occurred (groups 2 and 4) and vacclnees were regularly informed about their immune status Passive active Immunization of HBsAg-posltlve or HBV-negatlve and pregnant vaccmees was practically devoid of side-effects It is doubtful whether the abortion 2 days after initial immunization was Indeed a direct adverse effect of immunization The first trimester abortion rate after IVF did not differ from that found for the period before HBV contamination of the culture medium was &scovered 5 In fact, immunization of pregnant women in case of high risk for hepatms B infection is advocated Despite statements of changes m immunity during pregnancy there is little evidence of impairment of cellular Immumty in pregnancy The ability to respond to HBsAg vaccine appeared to be adequate19
This study provided the opportunity to determine whether admlnlstratmn of HBIg and recombinant HB-vacclne to adults in a high risk Sltuatmn consistently led to protective levels of antl-HBs soon after immunization The first dose of HBIg resulted in a protective level
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of antl-HBs in all but two cases Subsequent HBIg and vaccine doses &d not produce a major Increase in antl-HBs levels, except for the booster dose of vaccine at month 6 In fact, admlmstratlon of a supplementary dose of HBIg at month 4 was thought to be necessary for the majority of the spouses of HBsAg-posltlVe women
The overall response rate to recombinant HBvaccine at month 7 was comparable to the response rate for hospital personnel Protective levels of antl-HBs before the booster dose were, however, relatively low (87% for both female groups and 48% and 81% (mean 63%) for groups 3 and 4, respectively, at month 6) compared with other studies of recombinant vaccine 2°-22 in which ~>93% of healthy adults had antl-HBs >~10mIU m1-1 at the time of the booster dose The 'intensive' immunization schedule with an extra dose of vaccine after 2 months did not appear to accelerate the immune response m females In fact, as far as postexposure prophylaxis is concerned, lmmunogenlclty after administration of recombinant vaccine was very disappointing in this study Recently, lwarson recommended an accelerated immunization schedule that would yield a more rapid antibody response 16 23 such a schedule might be an alternative to HBIg in combination w~th HB-vacclne in the postexposure situation This study, with a vaccine schedule of 0, 2 and 6 weeks, did not yield satisfactory antibody levels at all, thus emphasizing the need for HBIg in postexposure prophylaxis Known factors that influence the immune response to vaccine include age, sex, antigen dose and number of doses given, site of injection and freezing of the vacclne24 25 Sex-related differences in immune response were found for the combined IVF groups but not for controls Age, dose, site of lnjectmn and vaccine were the same for the IVF groups and controls Could the large doses of HBIg have interfered with the development of anti-HBs after immunization9 Studies of the concurrent administration of HBIg and plasma derived vaccine at one or two occasions showed that the results were similar to those obtained with vaccine alone 9 26-28 Szmuness et al 2s found that rejection of 300 IU of HBIg did not Inhibit the antl-HBs response to 20/tg doses of HBvaccine (Heptavax B, Merck Sharp & Dohme) in adults In neonates, two major studies have yielded conclusive evidence in favour of the dual approach of postexposure prophylaxis by combination of passive active immunization la 29 The attack rate for development of the persistent carrier state in neonates of HBeAgpositive HBsAg carrier mothers was 90% in untreated groups Both HBIg alone or vaccine alone had 70 80% efficacy while efficacy rates in the groups given dual prophylaxis were above 90% 13 There was no statlstmally significant advantage from multiple doses as opposed to a single dose of immune globuhn in conjunction w~th hepatms B vaccine for efficacy nor for immune response (GMT) 29
Yet, it cannot be excluded with certainty that an mhxbmng effect of HBIg was masked by the high dose of the vaccine used in these studies To 
